AFP and hepatocellular carcinoma: Subgroup analysis of OS showed a trend for better outcome (HR [95% CI]) in: (i) low baseline level of AFP < 200 ng/mL (HR 0.68 [0.49–0.96]) vs. high level (HR 0.88 [0.62–1.26]) by contrast with nivolumab in CheckMate-459; and (ii) in HBV-related HCC (HR 0.57 [0.35–0.94]) vs. HCV (HR 0.96 [0.48–1.92]) vs. non-viral (HR 0.88 [0.64–1.20]) in accordance with nivolumab in CheckMate-459 for HBV and non-viral subsets.